HemOnc Today Current Issue

The following articles appeared in the print edition of HemOnc Today.

Table of Contents

• Strict cancer trial eligibility criteria ensure patient safety, but ‘pendulum has swung too far’
• Should criteria for adult oncology trials be relaxed so those aged younger than 18 years can participate?
• Natural language processing and the practice of hematology/oncology John Sweetenham, MD, FRCP, FACP
• Erroneous reporting vs. erroneous interpretation of liquid biopsy results Wafik S. El-Deiry, MD, PhD, FACP
• Report: ‘Misguided public policies’ fueled shift of cancer care into more expensive hospital setting
• Novel transplant protocol potentially curative approach for sickle cell disease
• Allogeneic transplant survivors at increased risk for cognitive decline
• Exercise reduces mortality among childhood cancer survivors
• ‘Much to learn’ about toxicity, outcomes with pembrolizumab for multiple myeloma
• Despite lower costs, minimally invasive hysterectomy may reduce cervical cancer survival
• Bevacizumab plus chemotherapy prolongs PFS for recurrent ovarian cancer
• Pexidartinib induces responses for tenosynovial giant cell tumor
• Gene test identifies women with early breast cancer who can be spared adjuvant chemotherapy
• Matched targeted therapy may enhance clinical outcomes for various cancers
• Chemotherapy-induced peripheral neuropathy persists for years in childhood cancer survivors
• Certain patients with melanoma may benefit from anti-PD-1 treatment after progression
• Ibrutinib plus venetoclax improves outcomes in poor-prognosis mantle cell lymphoma
• Carfilzomib-based therapy extends OS in relapsed, refractory multiple myeloma
• Cancer survivors more likely to be prescribed multiple medications
• Prevalence of clonal hematopoiesis may confound tumor-only genomic profiling results
• Smoking during prostate cancer treatment increases risk for metastases, mortality
• Surgeons may influence genetic testing for breast cancer
• Pancreatic adenocarcinoma mortality risk outweighed by other causes after 9 years
• Osimertinib not cost-effective for EGFR-mutated lung cancer
• FDA approves Avastin plus chemotherapy for ovarian cancer after surgery
• FDA approves Keytruda for primary mediastinal large B-cell lymphoma
• FDA grants priority review to Imbruvica-Rituxan combination for Waldenström’s macroglobulinemia
• FDA accepts application for Opdivo-Yervoy, first immuno-oncology combination for lung cancer
• FDA approves Braftovi-Mektovi combination for BRAF-mutated melanoma
• FDA grants priority review to glasdegib for treatment-naive acute myeloid leukemia
• FDA approves Opdivo-Yervoy combination for subset of patients with metastatic colorectal cancer
• FDA grants priority review to Keytruda plus chemotherapy for lung cancer subtype
• FDA grants priority review to Keytruda for advanced liver cancer
• Multidisciplinary approach crucial to support adolescents, young adults with hematologic malignancies
• US Oncology Network names chief surgical officer
• Leukemia & Lymphoma Society appoints board members, names chief operating officer
• AACR presents grant for transformative cancer research
• Radiation oncologists join NYU Langone Health’s Perlmutter Cancer Center
• Ruxolitinib shows promising response rate for graft-versus-host disease
• Atezolizumab plus chemotherapy improves survival for small cell lung cancer
• Luspatercept improves red blood cell transfusion independence in myelodysplastic syndrome
• First-line olaparib prolongs PFS in BRCA-mutated ovarian cancer